Background
==========

A gene signature is a group of genes whose expression pattern represents the status of a gene expression disease \[[@B1]\]. By using the microarray technology, which has developed rapidly in last ten years, various gene signatures are developed for various complex diseases, especially the cancer. Since researchers found that gene-expression signatures are able to predict clinical outcome of breast cancer in 2002 \[[@B2],[@B3]\], it have become a hot topic and attracted the attention of both biologists and oncologists. Signatures for various phenotypes, such as poor prognosis \[[@B3]\], invasiveness \[[@B4]\], recurrence \[[@B5]\], and metastasis \[[@B6],[@B7]\], have been experimentally derived from patient groups and biological hypotheses. However, distinct signatures share very few genes, even though they paradoxically occupy a common prognosis space. For both cancer biologists and oncologists, a critical problem is whether these disjoint genetic signatures can provide a unified insight on the relationship between gene expression and clinical outcome.

Obviously, complex heterogeneity of signatures caused by different probe design, different platforms, or inadequate patient samples, becomes an obstacle when trying to integrate various signatures of breast cancer. Gene Ontology enrichment, pathway analysis, and some genome-scale methods are proposed to explain the lack of overlap \[[@B8]-[@B10]\]. In literature \[[@B8]\], the authors list five possible explanations for the small overlap between signatures:

1\. Heterogeneity in expression due to different platform technologies and references;

2\. Differences in supervised protocols with which signatures are extracted;

3\. Although the genes are not exactly the same, they represent the same set of pathways;

4\. Differences in clinical composition between datasets (i.e. sample heterogeneity);

5\. Small sample size problems that cause inaccurate signatures.

Through a large-scale analysis that performed on 947 breast cancer samples from Affymetrix platform, the authors of literature \[[@B8]\] conclude that the small signature overlap is most likely due to small sample size problem (explanation 5). However, the conclusion might be specific to the datasets and the specific techniques used in their work. By comparison of three prognostic gene expression signatures for breast cancer, literature \[[@B9]\] suggested that the small overlap between the different prognostic gene signatures is because these different signatures represented largely overlapping biological processes (explanation 3). By taking into account the biological knowledge that exists among different signatures, the authors of \[[@B10]\] found that different signatures are similar at biological level, rather than gene level (explanation 3). Much work has been done in an effort to understand the small overlap between gene signatures, but so far there is no widely accepted explanation.

Meanwhile, computational biologists have developed Protein Interaction Networks(PIN) that effectively have been used to analyze protein interactions underpinning share sub-phenotypes among otherwise seemingly disparate disease, such as retinitis pigmentosa, epithelial ovarian cancer, inflammatory bowel disease, amyotrophic lateral sclerosis, Alzheimer disease, type 2 diabetes, coronary heart disease \[[@B11]\] and head and neck tumor metastasis \[[@B12]\]. For an individual expression signature in breast cancer, protein interaction networks are successfully used to predict prognosis \[[@B13]\] and detect subnetwork signatures of metastatic disease \[[@B4]\]. More recently, in \[[@B14]\], on genome-wide coexpression networks for different disease states, the authors used univariate Cox model and Relief algorithm to select the genes that are the most predictive of clinical outcome to construct gene signature for lung cancer. A 13-gene lung cancer prognosis signature with significant prognostic stratifications is identified by this method. By Single Protein Analysis of Net-works(SPAN \[[@B12]\]) and conservative permutation re-sampling, a small, but more biological significant breast cancer signature consisted by 54 genes is identified from a protein interaction network include 250 cancer-related genes curated from literatures \[[@B15],[@B16]\]. In reference \[[@B10]\], by integrating biological knowledge and different signatures, the authors derived a unified signature that is more robust than original signatures.

However, to integrate different breast cancer signatures, most existing methods need cancer domain knowledge, such as cancer-related literature used in \[[@B10],[@B15],[@B16]\]. This limited the application of these methods. In this paper, we describe a method to integrate different breast cancer signatures by using graph centrality in a context-constrained PIN for human breast cancer which is constructed by integrating disjoint gene signatures reported in previous literatures. Unlike most existing methods, the method proposed in this paper is able to integrate distinct gene signatures without cancer domain knowledge. By Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and relating our results to previous biological studies, we show that the genes in centrality-based signatures are tightly related to breast cancer and are able to predict clinical outcome.

Methods
=======

To identify reliable gene signature of breast cancer by integrating various gene signatures, we propose a graph centrality based method to identify disease genes from a constrained PIN and the overview of this method is provided in Figure [1](#F1){ref-type="fig"}. Briefly, as shown in Figure [1](#F1){ref-type="fig"}, the method proposed here has three steps:

![**Schematic overview of graph centrality based integration of gene signatures**. Schematic overview of graph centrality based integration of distinct breast cancer gene signatures.](1752-0509-5-S3-S10-1){#F1}

1\. Collect genes from different breast cancer gene signatures, and discard the genes that exist in only one signature.

2\. Project the genes collected in Step 1. to human PIN to construct a context-constrained PIN that consisted. Therefore, to some extent, all genes in this context-constrained network are related to breast cancer. However, we don\'t know which genes are the most important ones to the breast cancer and can be used to predict clinical outcome.

3\. To determine the relationship between genes and breast cancer, we calculated graph centrality of each gene in this constrained PIN. Since the constrained PIN is built based on breast cancer gene signatures, graph centrality of genes in this network indicates their relationship to breast cancer. Output given number of genes with highest graph centrality as the new unified breast cancer signature.

Details of the three steps are described in following three subsections and then validation methods are presented.

Collecting genes from different signatures
------------------------------------------

GeneSignDB (<http://compbio.dfci.harvard.edu/genesigdb/>) \[[@B17]\] is a curated gene signatures database that collected gene signatures for various species and diseases. Keywords \"breast cancer\" for disease and \"human\" for species are used to search gene signatures for human breast cancer in GeneSignDB. 94 distinct human breast cancer signatures are obtained, which are reported in 58 different literatures. Since the genes which are included in only one gene signature may be generated by chance, we discard these unreliable genes.

Construction of context-constrained PIN
---------------------------------------

A complete human PIN is constructed by integrating protein interaction data from Human Protein Reference Database (HPRD) and BioGRID interaction database \[[@B18],[@B19]\]. After removal of duplicate edges and self-interactions, we got a PIN that is consisted by 51057 distinct interactions among 11465 proteins.

Then, the genes we collected in the first step are projected to the complete human PIN and a constrained PIN for human breast cancer is obtained. This constrained PIN contains 2924 proteins and 4698 interactions.

Use graph centrality to quantify the relationship between genes and breast cancer
---------------------------------------------------------------------------------

Various definitions of graph centrality have been proposed from different perspectives to evaluate the importance of nodes in a graph. The concept has been widely used in bioinformatics, such as discovery of essential proteins in protein networks \[[@B20]\]. Because it is difficult to infer which definition is best for identifying disease genes in the context-constrained network, we evaluated six different definitions in our work.

For a protein interaction network *G(V,E)*, the six measurements of centrality used in this study are defined as following:

• Degree centrality(*DC*): The degree centrality *DC*(*i*) of vertex *i*is the number of edges connecting node *i*and its neighbors \[[@B21]\].

$$DC\left( i \right) = Deg\left( i \right),$$

where *Deg*(*i*) is the degree of vertexes *i*.

• Betweenness centrality(*BC*): The betweenness centrality *BC*(*i*) of a node *i*is the average fraction of shortest paths that pass through the node *i*\[[@B22]\].

$$BC\left( i \right) = \sum\limits_{s}\sum\limits_{t}\frac{\sigma_{st}\left( i \right)}{\sigma_{st}},s \neq t \neq i,$$

where *σ*~*st*~denotes the total number of shortest paths between *s*and *t*and σ~*st*~(*i*) denotes the number of shortest paths from *s*to *t*that pass through the node *i*.

• Closeness centrality(CC): The closeness centrality *CC*of node *i*can defined as \[[@B23]\]:

$$CC\left( i \right) = \frac{1}{\sum_{j \neq i}c_{p}\left( {i,j} \right)}$$

*CC*is a global metric which describes how the given node *i*connects to other nodes.

• Subgraph centrality(SC): The subgraph centrality *SC*(*i*) of node *i*can be defined as \[[@B24]\]:

$$SC = \sum\limits_{l = 0}^{\infty}\frac{\mu_{l}\left( i \right)}{l!},$$

where *μ*~*l*~(*i*) denotes the number of closed walks of length *l*which starts and ends at node *i*.

• Eigenvector centrality(EC): The eigenvector centrality *EC*(*i*) of node *i*is defined as the *i*th component of the principal eigenvector of *A*, where *A*is an adjacent matrix. Let λ be an eigenvalue and *e*be the eigenvector. Then for an equation *λe*= *Ae*, we can obtain *EC(i) = e*~1~(*i*), where *e*~1~corresponds to the largest eigenvalue of *A*\[[@B25]\].

• Information centrality(IC): The information centrality *IC*(*i*) of node *i*in a is defined as \[[@B26]\]:

$$IC\left( i \right) = \left\lbrack {\frac{1}{n}\sum\limits_{j}\frac{1}{I_{ij}}} \right\rbrack^{- 1},$$

where *n*is the number of nodes in graph *G*and *I*~*ij*~= (*r*~*ii*~+ *r*~*jj*~- *r*~*ij*~) - 1, where *r*~*ij*~is the element of matrix *R*. Let *D*be a diagonal matrix of the weighted degree of each node and *J*be a matrix with all its elements equal to one. Then, we get *R*= (*r*~*ij*~) = \[*D*- *A*+ *J*\] - 1. For computational purposes, *I*~*ii*~is defined as infinite. Thus, $\frac{1}{I_{ii}} = 0$.

High centrality of a gene indicates that it is important to the constrained PIN and probably plays an important role in mechanism of breast cancer development. Therefore, according to the graph centrality of genes, we get a gene list that is ordered by the genes\' importance to human breast cancer. Depending on specific purpose, a given number of top genes can be selected to construct a reliable gene signature of breast cancer. The reliable gene signature is the integration of the disjoint original signatures.

KEGG pathway and Gene Ontology enrichment analysis
--------------------------------------------------

*p*-value based on the hypergenometirc distribution is widely used as a measurement of the extent to which the clusters are annotated by a specific GO term \[[@B27]-[@B30]\]. Basically, the *p*-value is defined as following:

$$P = 1 - \sum\limits_{i = 0}^{k - 1}\frac{\begin{pmatrix}
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where *C*is the size of the gene set containing *k*gene with a given GO term; *G*is the size of the universal set of known genes and contains *n*genes with the annotation.

Low *P*in Formula 6 indicates that the module closely corresponds to the GO annotation because the network has a rare chance to produce the module. To simplify our analysis, we define *p*-score as the negative of *log(P)*with the annotation \[[@B31]\].

Gene set enrichment analysis for KEGG pathways is very similar to the one for GO annotations. In Equation 6, *C*is the size of the gene set containing *k*genes that exist in a given KEGG pathway; *G*is the size of the universal set of known genes and contains *n*genes that exist in the pathway. Similarly, *p*-score can be used to measure the relationship between the gene set and a specific KEGG pathway.

In this study, both KEGG and GO enrichment analysis are performed on DAVID \[[@B32]\].

Validate on microarray dataset
------------------------------

To evaluate the signature\'s ability to predict clincal outcome, we used expression intensity of the genes in the signature to cluster microarray datasets of breast cancer patients with different pathologic parameters. Patients with similar pathologic parameters should be clustered togather. For a given pathologic parameter, the *p*-value of the clustering result indicates the signature\'s ability to predict the pathologic parameter.

In this study, euclidean distance between samples are calculated by using the expression intensity of genes in gene signature. Then hierarchical clustering is used to cluster the microarry datasets of breast cancer patients.

Results
=======

Overlap among breast cancer signatures
--------------------------------------

As mentioned in Methods section, 94 breast cancer gene signatures are obtained from public database. Since the different generation methods and the various purposes of these signatures, the size of these signatures are very different. The biggest signature contains 3260 genes, and the smallest signature only contains 4 genes. The median size of these signatures is 46.

To evaluate the similarity among these gene signatures, we analyze the overlap among the 94 gene signatures (see Table [1](#T1){ref-type="table"}). The analysis result is very consistent with the results reported in literature \[[@B15]\]. A very small overlap is found among different signatures. 4143 (58.6% of the total number) genes are found in only one signature, but only 24(0.4%) genes overlapped 10 or more signatures, and none of the genes overlapped all 94 signatures. The lack of overlapping is an obstacle to integrate various signatures of breast cancer.

###### 

Overlap among 94 breast cancer gene signatures

  Frequency          1      2      3     4     5     6    7    8    9    10   11   12   14   15   16   17
  ------------------ ------ ------ ----- ----- ----- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  **Num of genes**   4143   1608   687   323   148   56   40   23   15   13   4    3    1    1    1    1

There is very small overlap among distinct breast cancer signatures. Most genes exist in only one signature, and only 24 genes are included in 10 or more signatures.

Centrality based gene signatures
--------------------------------

All genes included in the 94 signatures are projected to the human PIN described in Methods section. In consideration of the lower reliability of gene signatures, only the genes that are included in two or more different signatures are used to construct the context-constrained PIN of breast cancer. Finally, this context-constrained PIN contains 2924 proteins and 4698 interactions.

Then, six graph centralities of each genes in this context-constrained PIN are calculated. Higher centrality for a gene indicates that the gene is more important to this network and should be more tightly related to breast cancer. Graph centrality of each gene in the context-constrained PIN is calculated and provided in Additional File [1](#S1){ref-type="supplementary-material"}. In a recent similar study performed by Chen *et.al*, based on a context-constrained network that obtained from literatures, 10 published gene signatures are integrated and a 54-genes signature is obtained \[[@B15]\]. This result is named as \"Chen\'s signature\" in the rest of this paper. For comparison, we also select 54 most important genes identified by each centrality definitions to construct gene signatures. Full list of genes in these graph centrality based signatures are provided in Table [2](#T2){ref-type="table"}.

###### 

Graph centrality based breast cancer signatures

  BC       CC        DC        EC        IC        SC
  -------- --------- --------- --------- --------- ---------
  TP53     TP53      TP53      TP53      TP53      TP53
  EGFR     ESR1      EGFR      ESR1      EGFR      ESR1
  CTNNB1   AR        EP300     EP300     EP300     EP300
  SMAD3    EGFR      ESR1      AR        ESR1      AR
  ESR1     EP300     BRCA1     BRCA1     BRCA1     BRCA1
  EP300    SMAD3     CREBBP    CREBBP    CREBBP    CREBBP
  SRC      BRCA1     SMAD3     SMAD3     AR        SMAD3
  BRCA1    CTNNB1    AR        EGFR      SMAD3     EGFR
  CREBBP   SRC       CTNNB1    HDAC1     SRC       HDAC1
  AR       CREBBP    SRC       STAT3     CTNNB1    STAT3
  UBE2I    AKT1      HDAC1     RB1       HDAC1     RB1
  DYNLL1   HDAC1     CASP3     CTNNB1    RB1       CTNNB1
  CASP3    STAT3     RB1       JUN       PIK3R1    JUN
  ACTB     STAT1     PIK3R1    SRC       CASP3     SRC
  AKT1     XRCC6     STAT3     AKT1      STAT3     AKT1
  HDAC1    RB1       UBE2I     SMARCA4   AKT1      SMARCA4
  PIK3R1   PIK3R1    AKT1      CDKN1A    SHC1      CDKN1A
  ZBTB16   PML       CDK2      PML       CDK2      PML
  ACVR1    UBE2I     PCNA      STAT1     JUN       STAT1
  RB1      HSPA8     SHC1      CDK2      STAT1     CDK2
  STAT1    CASP3     JUN       NCOA6     UBE2I     NCOA6
  HGS      CDK2      DYNLL1    HDAC2     CDKN1A    HDAC2
  CDK2     SMARCA4   STAT1     PIK3R1    PCNA      PIK3R1
  YWHAZ    CDKN1A    ACTB      UBE2I     HDAC2     UBE2I
  BCL2     JUN       CDKN1A    XRCC6     SMARCA4   XRCC6
  XRCC6    CDH1      MAPK14    HIF1A     NFKB1     HIF1A
  STAT3    YWHAZ     YWHAZ     NFKB1     CDH1      NFKB1
  PLK1     MAPK14    BCL2      CASP3     ACTB      CASP3
  PCNA     PRKDC     HDAC2     E2F1      MAPK14    E2F1
  HSPA8    HIF1A     ATM       CEBPB     LYN       CEBPB
  FN1      SHC1      LYN       PRKDC     XRCC6     PRKDC
  VIM      STUB1     NFKB1     SHC1      ATM       SHC1
  CD44     HDAC2     XRCC6     NCOA2     ZBTB16    NCOA2
  MAPK14   ERBB2     CDH1      CCND1     E2F1      CCND1
  GNB2L1   HSPA4     SMARCA4   PCNA      YWHAZ     PCNA
  FANCA    BCL2      EZR       TDG       BCL2      TDG
  EEF1A1   ZBTB16    HGS       ERBB2     PML       ERBB2
  SKIL     LYN       ZBTB16    HSPA4     JAK1      HSPA4
  SHC1     NCOA6     PLK1      ZBTB16    EZR       ZBTB16
  USP7     PAK1      CAV1      RXRA      PRKDC     RXRA
  CAV1     MDM4      E2F1      MAPK14    JAK2      MAPK14
  JUN      CASP8     JAK1      JAK2      CASP8     JAK2
  RXRA     CEBPB     RXRA      STUB1     RXRA      STUB1
  LYN      NFKB1     FN1       CDK7      ERBB2     CDK7
  CDKN1A   JAK2      HSPA8     PTPN6     HIF1A     PTPN6
  HIF1A    PTPN6     VAV1      ATM       CAV1      ATM
  ATM      HGS       ACVR1     BCL3      HSPA8     BCL3
  EZR      EZR       CASP8     DDX5      VAV1      DDX5
  PPP1CA   CAV1      HIF1A     RBL1      CDKN2A    RBL1
  PAK1     PIAS4     JAK2      FOS       NCOA6     FOS
  PLSCR1   TDG       PML       CDH1      PTPN6     CDH1
  TGFBR2   IGF1R     CDKN2A    MDM4      DYNLL1    MDM4
  AURKA    DDX5      EEF1A1    ING1      HGS       ING1
  KPNB1    MET       ERBB2     SIN3A     SIN3A     SIN3A

54 genes with highest graph centrality in the context-constrained PIN are selected to consist new breast cancer gene signatures. The genes in the six signatures identified by six graph centrality measurements are listed in this table.

Since all the six graph centrality definitions are designed to measure the importance of a node to a graph, gene signatures identified by the six centrality measurements are similar with each other. A extremely case is all the top 54 genes identified by *EC*and *SC*are the same. By contrast, overlap between our results and Chen\'s gene signature is only 5-8(9.3%-14.8%, p-value \< 0.05).

An interesting result is found in our work. No matter which centrality measurement is used to evaluate the importance of genes in the context-constrained network, TP53 gene, which is already known as a tumor suppressor, is always the most important gene. Another similar example is breast cancer type 1 susceptibility protein (BRCA1). As we expected, our result also shows that BRCA1 plays an important role in the breast cancer. Other similar examples include epidermal growth factor receptor (EGFR), E1A binding protein p300(E300), Androgen receptor gene(AR) and so on (see Table [2](#T2){ref-type="table"}).

However, another well-known breast cancer gene, BRCA2, is not included in any signature identified by the six centrality measurement. This is because BRCA2 is included in only one original signature and was discarded when we constructed the context-constrained PIN. On the one hand, the absence of BRCA2 is also a evidence to prove that the quality of existing breast cancer gene signatures is low, and on the other hand, the absence of BRCA2 in out signature indicates that our method can be improved by refining the signature genes collection method.

Relationship among genes in gene signatures
-------------------------------------------

To investigate the relationship among genes in the gene signatures, seven sub PINs are constructed by projecting genes in each gene signature to the complete human PIN. As shown in Table [3](#T3){ref-type="table"}, the sub PINs consisted by the genes in the graph centrality based gene signatures are much denser than that consisted by the genes in Chen\'s signature. We also can observe the significant difference in Figure [2](#F2){ref-type="fig"}. The most dense networks are consisted by the disease genes that are identified by *EC*and *SC*.

###### 

Topological size of context-constrained PINs.

         Proteins   Interactions
  ------ ---------- --------------
  BC     54         238
  CC     54         330
  DC     54         279
  EC     54         352
  IC     54         312
  SC     54         352
  Chen   54(35)     70

To investigate the differences between graph centrality based gene signatures and that reported in previous literature, topological size of sub-network consisted by the genes in these gene signatures are calculated and presented in this table. It should be note that the sub-network consisted by the genes included in Chen\'s gene signature is not a connected graph. The number in parenthesis is the number of proteins of its biggest connected component.

![**Sub-networks consisted by the genes of different signatures**. The first six sub-networks are consisted by the signature genes identified by six graph centrality measurements, repectively. The last one is consisted by the signature genes identified by Chen. Compared with Chen\'s result, all the sub-networks that consisted by the genes of the signatures that identified by graph centrality are connected graph and denser.](1752-0509-5-S3-S10-2){#F2}

KEGG pathways enrichment analysis
---------------------------------

As shown in Table [4](#T4){ref-type="table"}, the most significant KEGG pathway of all six graph centrality-based gene signatures are \"pathways in cancer\", but that of Chen\'s gene signature is \"Cell cycle\". Chen\'s gene signature is also annotated by \"pathways in cancer\", but the *p*-score is very low. It is obvious that graph centrality based method is more powerful than SPAN to identify cancer related genes in a constrained PIN.

###### 

KEGG pathways enrichment analysis results.

  Method   KEGG Pathway   Description          Annotated Genes   Corrected *p*-score
  -------- -------------- -------------------- ----------------- ---------------------
  BC       hsa05200       pathways in cancer   23                13.09
  CC       hsa05200       pathways in cancer   29                18.92
  DC       hsa05200       pathways in cancer   31                21.59
  EC       hsa05200       pathways in cancer   28                25.74
  IC       hsa05200       pathways in cancer   30                20.22
  SC       hsa05200       pathways in cancer   28                25.74
  Chen     hsa04110       Cell cycle           25                26.80
  Chen     hsa05200       pathways in cancer   11                2.59

To investigate the relationship between the gene signatures and cancer-related pathways, KEGG pathway enrichment analysis is preformed on these signatures.

GO enrichment analysis
----------------------

Biological process GO enrichment analysis is performed on each gene signatures (see Table [5](#T5){ref-type="table"}). For each signature, the GO biological process with highest p-score and corresponding p-score are presented in Table [5](#T5){ref-type="table"}. Unlike the genes identified in Chen\'s study \[[@B15]\], which is annotated by term \"cell cycle\", five centrality-based gene signatures are annotated by \"positive regulation of macromolecule metabolic process\" and only the gene signature identified by *BC*is annotated by \"response to organic substance\".

###### 

Gene Ontology enrichment analysis results.

  Method   GO Term      Description                                              *p*-score
  -------- ------------ -------------------------------------------------------- -----------
  BC       GO:0010033   response to organic substance                            21.44
  CC       GO:0010604   positive regulation of macromolecule metabolic process   21.44
  DC       GO:0010604   positive regulation of macromolecule metabolic process   17.50
  EC       GO:0010604   positive regulation of macromolecule metabolic process   25.74
  IC       GO:0010033   response to organic substance                            19.60
  SC       GO:0010604   positive regulation of macromolecule metabolic process   25.74
  Chen     GO:0007049   cell cycle                                               19.94

To investigate the relationship between the gene signatures and cancer-related biological processes, Gene Ontology enrichment analysis is preformed on these signatures.

The structure of GO terms is a tree-like structure (see Figure [3](#F3){ref-type="fig"}. The term \"regulation of biological regulation\", which is located at the same level of \"cell cycle\", is the ancestor of \"positive regulation of macromolecule metabolic process\". According to G2SBC database \[[@B33]\], only 190 breast cancer genes are annotated by \"Cell Cycle\", but 1159 breast cancer genes are annotated by \"regulation of biological process\". This indicates that the gene signatures identified by graph centrality are probably more tightly related to breast cancer.

![**Relationship among most significant GO terms annotate to significant breast cancer genes identified by different methods**. Relationship among most significant GO terms annotate to significant breast cancer genes identified by different methods. Green boxes indicates the GO terms annotate to genes identified by centrality, and red box indicate the GO term annotate to Chen\'s results.](1752-0509-5-S3-S10-3){#F3}

According to the *p*-score, both the two types of enrichment analysis suggested that *EC*and *SC*are probably the best choices to identify disease genes from context-constrained network and integrate different gene signatures. As reported in literatures, *SC*also has superior performance in the discovery of essential proteins in protein interaction network \[[@B34]\] and essential proteins tend to have higher correlation with dominant and recessive mutants of disease genes \[[@B35]\]. This is possibly the reason that *SC*and *EC*outperformed other centrality measurements. We also note that the PINs that are consisted by the disease genes identified by *EC*and *SC*are denser than that of other centrality measurements(see Table [3](#T3){ref-type="table"}). This indicates that breast cancer genes have tight and complicated relationship with each other.

Validate of the prognostic potential of the subgraph centrality based gene signature
------------------------------------------------------------------------------------

Since *SC*and *EC*outperform in functional enrichment analysis, we tested the *SC*and *EC*based gene signatures in a genome-wide microarray dataset: GSE7390 \[[@B36]\]. This microarray dataset is downloaded from NCBI GEO database and includes 198 breast cancer patients width different pre-diagnosed pathologic parameters.

We analyze the relationship between the *SC*based signature genes and hormone receptor status using hierarchical clustering. The 198 patients in GSE7390 were divided into two main clusters (Additional File [2](#S2){ref-type="supplementary-material"}), the first cluster includes 118 samples, and the second cluster includes 80 samples. The mean value of each attribute of the samples in each cluster are listed in Table [6](#T6){ref-type="table"}. As shown in Table [6](#T6){ref-type="table"}, the tumor size and NPI Score of the first cluster is smaller than those of the second cluster. Disease-free survival time, overall survival time, distant metastasis-free survival time, 10-year overall survival probability and time to distant metastasis of the patients in the first cluster is longer than those of the patients in the second cluster. In another word, the condition of patients in the first cluster is much better than the second cluster of patients.

###### 

Clinical outcome of two main clusters

                                            118 samples cluster   80 samples cluster
  ----------------------------------------- --------------------- --------------------
  Patient Age                               47                    45
  Tumor Size(mm)                            2.06                  2.36
  Disease-free survival (days)              3498                  3252
  Overall survival (days)                   4391                  3792
  Distant metastasis-free survival (days)   4148                  3667
  Time to distant metastasis (days)         4148                  3667
  NPI Score                                 3.4                   4.17
  10-year overall survival probability      83.38                 74.98

Mean value of each clinical outcome recorded in the microarray dataset of the samples in each cluster is presented in this table.

In the first cluster of patients, 104 of them were ER+; and in the second cluster of patients, only 30 of them were ER+. The *p*-value calculated by ANOVA is 2.47 × 10^-13^. We also explored the relationship between the signature genes and the time to distant metastasis. In the first cluster, the time to distant metastasis of 97 patients were longer than 2000 days; and in the second cluster, that number is only 55. The *p*-value is 0.04254. Normally, *p*-value that smaller than 0.05 means the result is statistic significant and is not generated by chance. Such small *p*-value of the clustering result indicates that the *SC*based signature is able to predict the clinical outcome very well.

Discussion and conclusion
=========================

Identification of genes which play important roles in the development of cancer is a critical problem needed to solve in current research of various cancers. Gene expression signatures provide a way to find significant cancer genes in given groups of patients. Due to the low overlap between heterogeneous signatures, how to integrate them is becoming a serious problem. Fortunately, as shown in this paper, graph centralities, especially *EC*and *SC*, are useful tools to integrate existing different cancer gene signatures.

As well-known, weighted protein interaction network can be constructed by integrating functional annotations, and centrality is also can be extended to weighted network easily \[[@B20]\]. More promising results should be found in the weighted protein interaction network. Besides this, other topological parameters from graph theory may improve this method as well.
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###### Additional file 1

**Graph centrality of genes in the context-constrained PIN**. In this study, graph centrality of each gene in the context-constrained PIN is calculated and used to quantify the relationship between genes and the breast cancer. The calculation results are provided in this additional file.
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###### Additional file 2

**SC-based gene signature based hierarchical clustering analysis of breast cancer microarray dataset by using SC-based gene signature**. According to the gene signature identified by SC, hierarchical clustering analysis is performed on the breast cancer microarray dataset, GSE7390, which include 198 breast cancer patients with various pathologic parameters.
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